New “Cicada” COVID‑19 Variant BA.3.2 Spreads Globally, Health Officials Monitoring

GLOBAL, April 4 — A newly recognised COVID‑19 variant designated BA.3.2 — widely referred to as the “Cicada” variant — is drawing attention from health officials worldwide due to its rapid spread and genetic distinctiveness. The strain has been detected in at least 23 countries and in multiple U.S. states, though experts emphasise there is no current evidence it causes more severe disease than existing variants.

Health authorities including the World Health Organization (WHO) have classified the Cicada strain as a Variant Under Monitoring (VUM) since late 2025, signalling increased global surveillance but not an immediate public health emergency.

The variant first emerged in South Africa in late 2024 but remained relatively unnoticed until it resurfaced and began spreading more widely in 2025, prompting broader genomic monitoring by national health agencies. Studies suggest BA.3.2 carries a high number of genetic mutations — around 70 to 75 — in its spike protein, the part of the virus targeted by antibodies and vaccines.

In the United States, waste‑water and clinical surveillance has detected the variant in at least 25 states, although it remains a minority strain compared with dominant COVID variants, according to the CDC’s genomic surveillance program.

Despite the variant’s spread, infectious disease experts say that symptoms appear similar to strains previously circulating, including fever, cough, sore throat, fatigue and respiratory issues, and that existing COVID vaccines and antiviral treatments still appear to provide protection against severe illness.

Public health officials have emphasised that BA.3.2’s presence does not currently indicate a surge in hospitalisations or mortality relative to earlier phases of the pandemic, and global COVID trends remain relatively stable. However, its unusually high number of mutations has raised questions about possible immune‑evasion mechanisms, prompting some researchers to study how well current vaccines and prior immunity protect against the strain.

In several regions, including parts of Europe and the U.S., monitoring shows BA.3.2’s prevalence increasing in wastewater samples — a key early indicator used by epidemiologists to track spread ahead of clinical case rises. Experts stress that continued surveillance, vaccination, and preventive measures remain important as the virus evolves.

Health agencies in countries such as Indonesia and others have reported they have yet to detect BA.3.2 domestically but continue routine surveillance to ensure early detection of any new introductions.

Although early data suggest BA.3.2 has yet to cause widespread clinical disruption, authorities are urging the public to stay informed, maintain basic hygiene practices and stay up to date with recommended COVID‑19 vaccinations.